

Kraig Biocraft Laboratories, Inc. Achieves new Company Record Ahead of Schedule with 5,000 genetic Insertions in a single week.

The New Record is a direct result of the Recent Reorganization of the Notre Dame Research Team.

Scientists see increase in transient expression as strong evidence of the viability of the DNA insertions.

EAST LANSING, Mich., February 10, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is pleased to announce that Dr. Fraser's research team recently accomplished five thousand genetic transfers in a single week using the newly designed DNA insertion packets. "Every DNA packet insertion has the potential to create a new recombinant fiber with commercial applications. The achievement of 5,000 such insertions in a single week is something that the Company would not have dreamed of in 2008," said CEO Kim K Thompson. "At the same time," Thompson continued, "Dr. Fraser is reporting a large increase in the team's observation of the occurrence of transient expression shortly after the gene transfers are preformed." Transient expression following a genetic insertion is seen by the research team as a strong indication of the viability of the genetic transfers.

The Company will have preliminary test results back on these five thousand genetic insertions in approximately 45 days. "More importantly," added Mr. Thompson, "the research team is now performing these gene transfers in large numbers on a regular basis. That means that there will be a nearly continuous group of gene transfers being tested. Every single gene insertion has the potential to create a new commercially viable spider silk polymer. With this number of gene insertions the odds of our developing a viable polymer are increasing exponentially."

The Company believes these dramatic increases in productivity are the direct result of Mr. Thompson's successful efforts to reorganize the research team in 2008.

For more information on Kraig Biocraft Laboratories, please visit the Company's web site: www.KraigLabs.com

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops", "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release

that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO
(517) 336-0807
info@KraigLabs.com